MYO vs UNH

Myomo continues to address a large, underserved neurological rehabilitation market with its MyoPro device, validated by strong regulatory clearances and expanding reimbursement. Q1 2026 results, reported on May 9, 2026, exceeded consensus estimates with $10.1M revenue and narrower EPS loss of ($0.07), building on previous operational improvements. The formalization of Horton Capital's 6.0% stake a...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...